Search PubMed⌕ Search

Biomedical subjects

Y Kanda

Publications and source records attributed to Y Kanda.

At least 235 records · Page 13Linked to original sources
PubMed1987

Yolk sac tumors of the ovary and the human yolk sac.

In the present study a comparison was made between human yolk sacs and yolk sac tumors. Tubules surrounded by several to as many as 10 endodermal cells and intracellular tubules in one endodermal cell were frequently observed. The tubules were seen abundantly in the yolk sac of a 4-week pregnancy, and they resembled the reticular pattern of the yolk sac tumor. It was also observed that the papillary endoderm, which contained blood cells in the center and protruded into the endodermal tubules, resembled the Schiller-Duval body of yolk sac tumor. Ultrastructurally the tumor cells were similar to the yolk sac endoderm. alpha-Fetoprotein was positive in the yolk sac endoderm until approximately the seventh week of pregnancy. Yolk sac tumor was also alpha-fetoprotein-positive. In other words, our study of human yolk sacs of 4- to 11-week pregnancies presumes that the yolk sac tumor resembles the endoderm of 4- to 7-week pregnancies.

Endoderm↗
PubMed1987

Effects of polyprenoic acid on thermal injury.

This study was designed to determine the effect of polyprenoic acid on wound healing in rats after thermal injury and to compare the effect with healing in vitamin A deficient controls and in retinol-fed vitamin A deficient rats. Both polyprenoic acid and retinol visibly accelerated wound healing after thermal injury. Both enhanced the induction of platelets in the peripheral blood but neutrophils were not affected by polyprenoic acid. Histologically, in the hypo-vitamin A rat, polyprenoic acid administration increased both capillary formation and also the production of fibroblasts and collagen deposition in the wound by comparison with control vitamin A deficient animals; similar effects were produced by retinol feeding. These results indicate that both polyprenoic acid and retinol can facilitate wound healing. 3H-thymidine incorporation into dermal tissues showed that in polyprenoid-fed rats capillaries multiplied 1.3 times, epithelial cells 2.1 times, and fibroblasts 2.0 times faster than those in vitamin A-deficient animals; 3H-thymidine incorporation was greater after polyprenoid feeding than after retinol feeding. Polyprenoid thus stimulates both collagen deposition and neo-vascularization within burns, and so accelerates healing.

Animals↗
PubMed1987

[A case of recurrent gastric cancer successfully treated with a combination of cisplatin and carmofur].

A 51-year-old man with recurrent gastric cancer was treated by combined administration of Cisplatin and Carmofur. The target sites were the abdominal lymph nodes and the area of invasion to the stomach. Cisplatin (50 mg/body/day) was given for 3 days, while Carmofur (400-800 mg/body/day) was administered daily in 1 course. After 1 course of administration, the target tumor was reduced in size and the therapy was continued. A complete response was confirmed by upper gastrointestinal roentgenography, endoscopy and echography after 8 courses of Cisplatin administration. The patient has survived for 2 years 6 months in a state of CR. This case suggests that a combination therapy of Cisplatin and Fluoropyrimidine derivatives might be effective for gastric cancer.

Aged↗
PubMed1986

[Primary malignant lymphoma of the rectum--a case report].

The patient was a 69-year-old woman who complained of bloody stools and abdominal pain. A tumor was removed with abdominoperineal excision, and histologic examination revealed malignant lymphoma associated with reactive lymphoreticular hyperplasia. The lesion was of the diffuse, medium-sized cell type according to the classification of the Japan Lymphoma Study Group.

Aged↗
PubMed1985

[Clinical investigation of basic fetoprotein (BFP) and carcinoembryonic antigen (CEA) in stomach cancer and lung cancer].

The object of present study is to investigate the clinical value of BFP and CEA in stomach and lung cancer. BFP-positive cases were found in 36.8% of 378 stomach cancer and in 65.2% of 89 lung cancer. CEA-positive cases revealed in 37.6% of 205 stomach cancer and in 65.6% of 64 lung cancer. In serum levels of BFP, there was no difference between differentiated type and undifferentiated type of stomach cancer by histological classification. In lung cancer, BFP levels in serum of large cell type were significantly higher than those of other types. The combination assay using BFP and CEA revealed 54.1% and 82.8% positive rate of stomach cancer and lung cancer, respectively. These results suggested that BFP and CEA assay appeared to be available for elevation of cancer diagnosis, especially useful for diagnosis of lung cancer.

Adenocarcinoma↗
PubMed1985

[A case of advanced gastric cancer showing complete cure by immunochemotherapy with FT-207 and OK-432 confirmed by thorough histologic examination of total gastrectomy matter].

A 57-year-old woman was referred to our hospital because of epigastric tumor on Jan. 16, 1980. Two advanced gastric carcinomas were recognized in the antrum and the corpus by X-ray and endoscopic examinations. The biopsy diagnosis was poorly differentiated adenocarcinoma. She was treated with FT-207 suppositories and subcutaneous injection of OK-432 without operation because of a suspicion of ascites and Virchow's metastasis. After five months, the tumor of the corpus disappeared, and, after nine months, that of the antrum changed to a scarlike lesion. On July 30, 1981, total gastrectomy with extended nodal dissection was performed. Histological examination revealed complete absence of carcinoma cells in the stomach and regional lymph nodes.

Adenocarcinoma↗
PubMed1985

[Therapeutic effect of sequential doses of methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced gastric cancer: comparison of intermediate-dose MTX with high-dose MTX].

Twenty-one patients were treated with sequential doses of MTX and 5-FU so as to be classified by MTX dosage into an intermediate MTX-dose group and a high MTX-dose group. In the intermediate-dose MTX group, the drug was given at a dosage of 100 mg/m2 intravenously (i.v.) and followed 1 hour later by 5-FU at 800 mg/m2 i.v. (dripping for 1 hour); the drugs were recycled every 1 week. In the high-dose MTX group, the drug was administered at a dose of 1.5 g/m2 i.v. (dripping for 2 hours) and followed 1 hour later by 5-FU at 1.5 g/m2 i.v. (dripping for 2 hours); the drugs were recycled every 2-3 weeks. Average MTX concentrations in serum at the start of 5-FU administration were 1.69 X 10(-5) and 1.33 X 10(-4) mol/l/h in the intermediate and high-dose MTX groups, respectively. Six (50%) of 12 patients adequately treated with intermediate-dose MTX had a partial response (PR), and one (14.3%) of 7 evaluable patients treated with high-dose MTX had a PR. Major toxicity included diarrhea (33.3%) in the intermediate-dose MTX group and hair loss (71.4%) in the high-dose MTX group. Hematological toxicity was mild in MTX group: six (50%) of 12 patients had a granulocyte count nadir less than 1,000/microliters and one (8.3%) of 12 patients had a platelet count nadir less than 10(5)/microliters in the intermediate-dose MTX group. Five (71.4%) of 7 patients had a granulocyte nadir less than 1,000/microliters and two (28.6%) of 7 patients had a platelet count nadir less than 10(5)/microliters in the high-dose MTX group.

Adult↗
PubMed1985

[Diagnostic values of serum type III procollagen N-terminal peptide in type IV gastric cancer].

Since increased synthesis of collagen has been demonstrated in tissue of type IV gastric cancer, we attempted to distinguish type IV gastric cancer from other cancers by measuring serum levels of type III procollagen N-terminal peptide (type III-N-peptide). Mean serum levels in type IV gastric cancer patients without metastasis were found to be elevated above normal values and developed a tendency to be higher than those in types I, II and III gastric cancer patients without metastasis. Highly positive ratios were found in patients with liver diseases including hepatoma and colon cancer, biliary tract cancer, and esophageal cancer patients with liver, lung or bone metastasis, but only 2 out of 14 of these cancer patients without such metastasis showed positive serum levels of type III-N-peptide. Positive cases in patients with type IV gastric cancer were obtained not only in the group with clinical stage IV but also in the groups with clinical stages II and III. In addition, high serum levels of type III-N-peptide in patients with type IV gastric cancer were seen not only in the cases with liver, lung or bone metastasis but also in cases with disseminated peritoneal metastasis alone. These results suggest that if the serum level of type III-N-peptide is elevated above normal values, type IV gastric cancer should be suspected after ruling out liver diseases, myelofibrosis and liver, lung or bone metastasis.

Carcinoembryonic Antigen↗
PubMed1984

[Clinical trial on the effect of tegafur (SF-SP)].

SF-SP capsules containing sustained release granules of tegafur were orally administered 800 mg, b.i. d. for more than 4 weeks in 20 cases of advanced cancer, 11 of whom were evaluable (stomach 7, colon 1, liver 1, bile 1 and pancreas 1). The evaluation of antitumor effects was based on criteria of the Japan Society for Cancer Therapy, which are are almost the same as those of WHO. One partial remission out of 7 cases of stomach cancer was obtained, and its duration was 40 weeks. Toxicities were anorexia, nausea and vomiting, diarrhea and stomatitis, one case each of anorexia, and nausea and vomiting occurred within 10 days after SF-SP administration. No bone marrow depression, hepatic and renal disorders occurred after long-term SF-SP administration. SF-SP seems to be useful in the treatment of patients with gastric cancer.

Adenocarcinoma↗
PubMed1984

[Combination chemotherapy of CIS-diamminedichloroplatinum (II) and fluoropyrimidine derivatives for advanced gastric cancer: a preliminary report].

A total of thirteen patients with histologically-proved adenocarcinoma of stomach took part in this study at Saitama Cancer Center between July 1982 and September 1983; nine patients were considered evaluable. There were 7 male and 2 female patients with a median age of 52 yrs (range 42-75) and a median performance status of 3 (range 2-4). Patients were treated with a two drug combination of cis-diammine dichloroplatinum (II) and fluoropyrimidine derivatives (tegafur, cormobur ). Three out of 9 evaluable patients (33.3%) had a partial response which lasted 10 months. 6+ months, and 5+ months, respectively. The major toxic effect was a gastrointestinal symptom which was generally manageable. Myelosuppression was mild.

Adenocarcinoma↗
PubMed1984

[A case of renal cell carcinoma in tuberous sclerosis followed by basic fetoprotein--a new carcinoembryonic protein].

There have been very few reports on renal malignancies in tuberous sclerosis and only 9 cases have been reported in the Japanese literature. A second case of renal cell carcinoma in tuberous sclerosis in Japan is reported. The present case is a 29-year-old male who visited our clinic with the chief complaint of right flank mass. The excretory urogram, and renal selective angiography suggested right benign renal tumor, possibly angiomyolipoma. But surgical exploration was performed because of the possibility of renal malignancy. The histological findings revealed renal cell carcinoma. At 18 months after operation, the patient died of multiple visceral metastasis, i.e., to lungs, left kidney and liver. In this case basic fetoprotein - a new carcinoembryonic protein - was measured and its level elevated gradually as the disease progressed. Judging from the measurement of basic fetoprotein in this patient it may be an efficient new tumor marker for renal cell carcinoma.

Adenocarcinoma↗
PubMed1984

[Effect of cis-diammine dichloroplatinum, vindesine sulfate combination chemotherapy for advanced esophageal carcinoma].

Eleven patients with advanced squamous cell carcinoma of the esophagus were treated with a two-drug combination of cis-diammine dichloroplatinum and vindesine sulfate at Saitama Cancer Center between July 1982 and September 1983. Median age was 71 years old (range: 47-48) and 8 patients were greater than 70 years old. Median performance status was 3 (range: 1-4) by Koyama -Saito Criteria. Male female ratio was 6:5. Of the 11 patents, three obtained partial response (27.3%), lasting 8 weeks, 20 weeks+, and 42 weeks-, respectively, and three patients had minor response (27.3%). The major toxic effects including myelosuppression, nausea and vomiting were in general manageable.

Aged↗